Estimated Market Presence of Veterinary PRP by Manufacturers

28, February, 2025 

Animal Health Market Analysis

By Kevin McCarthy

Although these are rough estimates, as vet-specific PRP market data isn’t broken out by company in public sources. Broader PRP market reports (e.g., $723.97M globally in 2023 per Precedence Research) lump human and vet together, with North America at 44%, but don’t drill down to vet-only shares or individual firms. Zoetis and Arthrex dwarf others in resources and vet market penetration. Vetirus’ acquisition of Enso with a device agnostic approach, could shift dynamics, but it’s too fresh (February 2025) for firm stats. Smaller players like Pulse, VetStem, and Pall cater to specific needs, while Companion’s small-animal focus carves a steady but limited chunk.

Zoetis      (Restigen® PRP) 

• Estimated       Influence: Likely the leader, maybe 25-30% of the vet PRP market. 
• Why:       Zoetis is a giant in animal health (think billions in annual revenue       across all products), with a massive distribution network and strong       equine focus. Restigen® PRP taps into their brand trust and R&D       muscle. They’re a go-to for large vet practices and equine specialists,       giving them a hefty slice of the pie.

Arthrex      (Angel® System and Vet Systems) 

• Estimated       Influence: Strong contender, around 20-25%. 
• Why:       Arthrex dominates human orthopedics and has adapted its tech for vets,       particularly in equine and canine orthopedics. Their adjustable,       high-quality systems appeal to specialists, though their higher cost       might limit them to premium clinics.

Vetirus      Pharmaceuticals (via Enso Discoveries - Rebound PRP) 

• Estimated       Influence: Growing fast, maybe 15-20% post-acquisition. 
• Why:       Pre-acquisition, Enso was a smaller player with Rebound PRP’s       affordability and device-agnostic edge. Vetirus’ February 2025 buyout       (per S&P Global Animal Health) adds scale—90% of their revenue is       animal health, and they’re pushing into Europe, Middle East, Africa, and       beyond. CEO Robert N. Jordan’s focus on low-cost adoption could spike       their share quickly.

Companion      Animal Health (Companion PRP Therapy) 

• Estimated       Influence: Solid niche, 10-15%. 
• Why:       Focused on small animals (dogs, cats), their portable, user-friendly       system suits smaller practices. They’re less dominant in equine or       large-scale settings, capping their reach compared to Zoetis or Arthrex.

Pulse      Veterinary Technologies (PULSE PRP) 

• Estimated       Influence: Around 5-10%. 
• Why:       A regenerative therapy specialist, they’re known in equine and small       animal circles, often paired with shockwave tech. Smaller scale and less       brand recognition keep them mid-tier.

VetStem      Biopharma (VetStem PRP) 

• Estimated       Influence: 5-10%. 
• Why:       VetStem’s PRP rides on their stem cell therapy reputation, appealing to       vets already in that ecosystem. It’s a complementary offering, not their       core, so their PRP share is modest.

Harvest      Technologies (SmartPrep® System) 

• Estimated       Influence: 5-10%. 
• Why:       Part of Terumo BCT, they bring high platelet yields from human medicine       to vets. Broad use but not vet-specific branding limits their veterinary       focus.

Pall      Corporation (Pall Veterinary PRP System) 

• Estimated       Influence: 3-5%. 
• Why:       Their filtration-based approach is unique but less common in vet       practice. Likely a smaller player, appealing to those wanting       alternatives to centrifugation.

Current trends shaping the market share include Zoetis and Arthrex leading in equine-heavy markets; Companion and VetStem thrive with pets. Vetirus’ “no special centrifuge” pitch could erode shares of pricier systems like Arthrex or Harvest as they expand globally.  The vet PRP market is growing (part of the broader RP CAGR of 15-17% through 2030s), driven by orthopedics and regenerative demand. Vetirus might leapfrog if their rollout succeeds.